SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Immuneering Presents Ongoing Phase 3 MAPKeeper 301 Trial Design

Immuneering presented the design and methodology of its ongoing Phase 3 MAPKeeper 301 trial at the ESMO Congress.

IMRX

Related stories